Concert Pharma (CNCE): 3 Reasons To Be Bullish - Stifel

September 26, 2016 9:32 AM EDT
Get Alerts CNCE Hot Sheet
Price: $9.39 +1.51%

Rating Summary:
    6 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 19 | New: 13
Trade CNCE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Stifel analyst, Adam Walsh, reiterated his Buy rating on shares of Concert Pharmaceuticals (NASDAQ: CNCE). KOL feedback, management meetings, and a journal publication reinforce the analyst's bullishness on CTP-543.

CTP-543 is still in P1 so shares do not yet reflect what could be a lower-risk, game-changing opportunity for the company. However, with P1 results expected to read out in 4Q16, a short, six-month P2 trial expected to launch in 1H17, and an upcoming FDA Patient-Focused Drug Development Meeting on AA, the analyst expects the Street to share his bullish outlook on the drug.

No change to the price target of $23.

For an analyst ratings summary and ratings history on Concert Pharmaceuticals click here. For more ratings news on Concert Pharmaceuticals click here.

Shares of Concert Pharmaceuticals closed at $10.15 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Stifel

Add Your Comment